Health In Tech (NASDAQ:HIT) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen cut shares of Health In Tech (NASDAQ:HIT) from a strong-buy rating to a buy rating in a research report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Health In Tech in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $2.50.

Health In Tech Stock Performance

HIT traded up $0.11 on Friday, hitting $2.91. The company had a trading volume of 382,036 shares, compared to its average volume of 1,065,197. The stock has a market capitalization of $164.09 million and a price-to-earnings ratio of 145.50. The stock has a fifty day moving average price of $3.08 and a 200-day moving average price of $1.93. Health In Tech has a 12-month low of $0.51 and a 12-month high of $7.59.

Hedge Funds Weigh In On Health In Tech

Several hedge funds have recently modified their holdings of HIT. XTX Topco Ltd acquired a new stake in Health In Tech in the 1st quarter worth approximately $59,000. Arete Wealth Advisors LLC purchased a new position in shares of Health In Tech in the first quarter worth $47,000. Jane Street Group LLC acquired a new stake in shares of Health In Tech during the first quarter worth $48,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Health In Tech during the first quarter worth $41,000.

About Health In Tech

Health in Tech, Inc engages in the provision of insurance technology platforms which offer a marketplace of processes in the healthcare industry. Its services include Stone Mountain Risk, eDIYBS, HI Card, HI Performance Network, and Ancillary Products. The company was founded by Tim Johnson in 2014 and is headquartered in Stuart, FL.